Bioprocessing White Papers
-
The Evolution Of Antibody-Drug Manufacturing
6/3/2024
Explore how ADC chemistry and manufacturing have evolved, the challenges this dynamic growth has created, and how CDMOs are adapting to these changes to meet customer needs, now and in the future.
-
Establishing Commercial Manufacturing Services For ADCs
6/3/2024
Explore how one organization built upon 15+ years of experience and an extensive knowledge base of biologics manufacturing to establish commercial-scale ADC manufacturing capabilities.
-
Tackling Cell And Gene Therapy Manufacturing Challenges
5/30/2024
Allogeneic therapies are gaining popularity due to diversity, scalability, and affordability. A partner with innovative solutions can help streamline the path from discovery to commercialization.
-
The Advantages Of A Blended Learning Approach In Operator Training
5/30/2024
Explore blended learning and its advantages over traditional operator training methods, which often reduce training to a repetitive but necessary checklist of reading and acknowledging procedures.
-
Benefits Of PCR-Based mRNA Manufacturing Processes
5/17/2024
Learn about a proprietary polymerase chain reaction (PCR) solution that was developed to overcome the challenges associated with pDNA that applies the high accuracy of PCR to mRNA manufacturing.
-
Bispecific Antibodies Unleashed
5/16/2024
Explore how leveraging expert CDMO partnerships can streamline the development process and enhance the efficacy of your bispecific antibody therapies.
-
The Current And Future Value Of mRNA Vaccines And Therapeutics
5/16/2024
Discover how decades of research have propelled mRNA technology to the forefront of therapeutic development and learn how our expertise is advancing mRNA drug development.
-
The Benefits Of End-To-End Formulation And Fill/Finish Of Biologics
5/16/2024
Proper formulation development has a huge impact on whether a technology transfer to clinical phase fill/finish is successful. Review the challenges of transitioning a promising drug candidate.
-
Rapid Characterization Of mAbs Against SARS-CoV-2 Delta Spike Protein
5/16/2024
Delve into the intricate workflow employed for the discovery and characterization of monoclonal antibodies (mAbs) targeting the Delta spike protein.
-
Leveraging Efficiency From CLD To Clinical Manufacturing Of mAbs
5/16/2024
Discover how our efficient strategies can propel your mAb from discovery to clinical manufacturing in as little as 18 months.